Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18597892 | 1.00 | MME (0.48) | MMEPPARGPPARAALDH1A1MAPT | |
| SCHEMBL18386378 | 0.91 | MME (0.43) | MMEPPARGPPARAALDH1A1MAPT | |
| SCHEMBL18597988 | 0.87 | PPARG (0.46) | MMEPPARGPPARAALDH1A1MAPT | |
| SCHEMBL14919221 | 0.87 | MME (0.52) | MMEPPARGPPARAGPR88MEN1 | |
| SCHEMBL11969895 | 0.87 | MME (0.52) | MMEPPARGPPARAGPR88MEN1 | |
| SCHEMBL16939261 | 0.86 | MME (0.55) | MME | |
| SCHEMBL16939264 | 0.82 | MME (0.69) | MMEPPARGGPR88CA12CA1 | |
| SCHEMBL11969564 | 0.82 | MME (0.69) | MMEPPARGGPR88CA12CA1 | |
| SCHEMBL20371160 | 0.82 | MME (0.51) | MMEPPARGPPARANPSR1 | |
| SCHEMBL20376371 | 0.79 | MME (0.42) | MMEPPARGPPARACA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014138053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4847/4885PPARA 4838/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.